Preclinical development scientists and non-clinical regulatory leads need to design IND-enabling toxicology study packages that satisfy FDA and EMA requirements for first-in-human clinical trials, selecting appropriate species, dose levels, study durations, and endpoints for novel therapeutic modalities (biologics, oligonucleotides, cell therapies) while managing programme cost and timeline.